Emerald Advisers LLC lessened its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,557,437 shares of the medical research company's stock after selling 124,777 shares during the quarter. Emerald Advisers LLC owned 1.21% of NeoGenomics worth $25,667,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Loomis Sayles & Co. L P acquired a new stake in shares of NeoGenomics in the 3rd quarter valued at about $17,807,000. Bellevue Group AG raised its stake in NeoGenomics by 34.2% during the third quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company's stock valued at $23,786,000 after buying an additional 410,516 shares in the last quarter. Jennison Associates LLC raised its stake in NeoGenomics by 18.7% during the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock valued at $24,963,000 after buying an additional 238,288 shares in the last quarter. Vanguard Group Inc. lifted its holdings in NeoGenomics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock worth $234,673,000 after buying an additional 195,793 shares during the last quarter. Finally, State Street Corp grew its position in shares of NeoGenomics by 1.6% in the 3rd quarter. State Street Corp now owns 4,958,582 shares of the medical research company's stock worth $73,139,000 after acquiring an additional 80,449 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on NEO shares. Benchmark cut NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. The Goldman Sachs Group decreased their price target on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Bank of America lowered their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Jefferies Financial Group began coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 target price on the stock. Finally, Needham & Company LLC lowered their target price on NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.60.
View Our Latest Analysis on NEO
NeoGenomics Stock Performance
Shares of NASDAQ:NEO traded up $0.07 during trading hours on Thursday, hitting $9.48. The stock had a trading volume of 1,753,970 shares, compared to its average volume of 821,729. The stock's fifty day simple moving average is $12.01 and its 200 day simple moving average is $14.40. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -15.29 and a beta of 1.28. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. NeoGenomics, Inc. has a 1-year low of $8.98 and a 1-year high of $19.12.
NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). The business had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. Sell-side analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.
NeoGenomics Profile
(
Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Read More
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
